A private medical device company, developed a revolutionary, bedside biologic wound care product, based on recreating the natural process of the body to heal wounds, the RD1.
The company completed a successful FDA IDE study in the USA with some of the world leaders in wound care, and is expecting to receive 510K clearance during 2017 and immediately commercialize the patented technology to the $20B US market of wound care.